March 1, 2019 08:18 AM EST
R&D

Im­muno­Gen's lead armed an­ti­body fal­ters in key ovar­i­an can­cer test as a monother­a­py — shares crash

Natalie Grover

Reporter

Im­muno­Gen’s lead armed an­ti­body — mirve­tux­imab so­rav­tan­sine — has failed a late-stage study as a monother­a­py in third line plat­inum-re­sis­tant ovar­i­an can­cer pa­tients, a miss that could de­rail stud­ies test­ing the drug as part of a com­bo.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times